Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 13-Feb-04 10:00 PM View:  | Mayleben Timothy M Chief Operating Officer | Esperion Therapeutics Inc/mi (ESPR) | 10-Feb-04 | Disposition (other) | 972 | -- | -- | (100%) 0.97K to 0 | |
| 09-Feb-04 10:00 PM View: | More Eileen M Director | Esperion Therapeutics Inc/mi (ESPR) | 05-Feb-04 | Disposition (change in control) | 31,185 | $35.00 | $1,091,480.00 | (100%) 31.18K to 0 | |
| 10-Feb-04 10:00 PM View: | Mayleben Timothy M Chief Operating Officer | Esperion Therapeutics Inc/mi (ESPR) | 05-Feb-04 | Option Exercise | 106,368 | -- | -- | 507% 20.98K to 127.34K | |
| 09-Feb-04 10:00 PM View: | Thomas Frank E VP, Finance & CFO | Esperion Therapeutics Inc/mi (ESPR) | 05-Feb-04 | Disposition (change in control) | 48,778 | $35.00 | $1,707,230.00 | (100%) 48.78K to 0 | |
| 09-Feb-04 10:00 PM View: | Krause Brian R VP Preclinical Res.& Discovery | Esperion Therapeutics Inc/mi (ESPR) | 05-Feb-04 | Option Exercise | 60,821 | -- | -- | 3766% 1.61K to 62.44K | |
| 09-Feb-04 10:00 PM View: | Dasseux Jean Louis H VP, Chemistry & Technologies | Esperion Therapeutics Inc/mi (ESPR) | 05-Feb-04 | Disposition (change in control) | 103,108 | $35.00 | $3,608,780.00 | (100%) 103.11K to 0 | |
| 09-Feb-04 10:00 PM View: | Brinkerhoff William F VP Business Development | Esperion Therapeutics Inc/mi (ESPR) | 05-Feb-04 | Option Exercise | 19,606 | -- | -- | 1413% 1.39K to 20.99K | |
| 09-Feb-04 10:00 PM View: | Brinkerhoff William F VP Business Development | Esperion Therapeutics Inc/mi (ESPR) | 05-Feb-04 | Disposition (change in control) | 20,994 | $35.00 | $734,790.00 | (100%) 20.99K to 0 | |
| 09-Feb-04 10:00 PM View: | Olukotun Adeoye Y Sr VP Clin & Reg Affairs, CMO | Esperion Therapeutics Inc/mi (ESPR) | 05-Feb-04 | Option Exercise | 6,157 | $16.24 | $99,989.70 | 100% 0 to 6.16K | |
| 09-Feb-04 10:00 PM View: | Olukotun Adeoye Y Sr VP Clin & Reg Affairs, CMO | Esperion Therapeutics Inc/mi (ESPR) | 05-Feb-04 | Disposition (change in control) | 6,157 | $35.00 | $215,495.00 | (100%) 6.16K to 0 | |
| 09-Feb-04 10:00 PM View: | Bayh Susan B Director | Esperion Therapeutics Inc/mi (ESPR) | 05-Feb-04 | Disposition (change in control) | 2,000 | $35.00 | $70,000.00 | (100%) 2.0K to 0 | |
| 09-Feb-04 10:00 PM View: | Cresswell Ronald M Director | Esperion Therapeutics Inc/mi (ESPR) | 05-Feb-04 | Disposition (change in control) | 10,000 | $35.00 | $350,000.00 | (100%) 10.0K to 0 | |
| 10-Feb-04 10:00 PM View: | Newton Roger S President & CEO Director | Esperion Therapeutics Inc/mi (ESPR) | 05-Feb-04 | Disposition (change in control) | 503,677 | $35.00 | $17,628,700.00 | (100%) 503.68K to 0 | |
| 10-Feb-04 10:00 PM View: | Mayleben Timothy M Chief Operating Officer | Esperion Therapeutics Inc/mi (ESPR) | 05-Feb-04 | Disposition (change in control) | 126,372 | $35.00 | $4,423,020.00 | (99%) 127.34K to 0.97K | |
| 09-Feb-04 10:00 PM View: | Dasseux Jean Louis H VP, Chemistry & Technologies | Esperion Therapeutics Inc/mi (ESPR) | 05-Feb-04 | Option Exercise | 97,358 | -- | -- | 1693% 5.75K to 103.11K | |
| 10-Feb-04 10:00 PM View: | Newton Roger S President & CEO Director | Esperion Therapeutics Inc/mi (ESPR) | 05-Feb-04 | Option Exercise | 137,630 | -- | -- | 38% 366.05K to 503.68K | |
| 09-Feb-04 10:00 PM View: | Thomas Frank E VP, Finance & CFO | Esperion Therapeutics Inc/mi (ESPR) | 05-Feb-04 | Option Exercise | 46,799 | -- | -- | 2365% 1.98K to 48.78K | |
| 09-Feb-04 10:00 PM View: | Krause Brian R VP Preclinical Res.& Discovery | Esperion Therapeutics Inc/mi (ESPR) | 05-Feb-04 | Disposition (change in control) | 62,436 | $35.00 | $2,185,260.00 | (100%) 62.44K to 0 | |
| 04-Feb-04 10:00 PM View: | Blair Henry E Director | Esperion Therapeutics Inc/mi (ESPR) | 30-Jan-04 | Option Sale | 10,000 | $34.60 | $346,000.00 | (100%) 10.0K to 0 | |
| 04-Feb-04 10:00 PM View: | Blair Henry E Director | Esperion Therapeutics Inc/mi (ESPR) | 30-Jan-04 | Option Exercise | 10,000 | $5.69 | $56,900.00 | 100% 0 to 10.0K | |
| 10-Feb-04 10:00 PM View: | Mayleben Timothy M Chief Operating Officer & CFO | Esperion Therapeutics Inc/mi (ESPR) | 28-Jan-04 | Gift | 29,000 | -- | -- | (58%) 49.98K to 20.98K | |
| 20-Jan-04 10:00 PM View: | Olukotun Adeoye Y Sr VP Clin & Reg Affairs, CMO | Esperion Therapeutics Inc/mi (ESPR) | 16-Jan-04 | Option Exercise | 20,000 | $16.24 | $324,800.00 | 625% 3.2K to 23.2K | |
| 20-Jan-04 10:00 PM View: | Olukotun Adeoye Y Sr VP Clin & Reg Affairs, CMO | Esperion Therapeutics Inc/mi (ESPR) | 16-Jan-04 | Sale | 3,200 | $34.65 | $110,876.00 | (100%) 3.2K to 0 | |
| 20-Jan-04 10:00 PM View: | Olukotun Adeoye Y Sr VP Clin & Reg Affairs, CMO | Esperion Therapeutics Inc/mi (ESPR) | 16-Jan-04 | Option Sale | 20,000 | $34.65 | $692,978.00 | (86%) 23.2K to 3.2K | |
| 05-Jan-04 10:00 PM View: | Krause Brian R VP Preclinical Res.& Discovery | Esperion Therapeutics Inc/mi (ESPR) | 31-Dec-03 | Acquisition (other) | 54 | $16.75 | $904.50 | 10% 0.53K to 0.58K | |
| 10-Feb-04 10:00 PM View: | Newton Roger S President & CEO Director | Esperion Therapeutics Inc/mi (ESPR) | 30-Dec-03 | Gift | 206,500 | -- | -- | (36%) 572.55K to 366.05K | |
| 02-Jan-04 10:00 PM View: | Thomas Frank E VP, Finance & Inves. Relations | Esperion Therapeutics Inc/mi (ESPR) | 30-Dec-03 | Option Exercise | 1,000 | $5.00 | $5,000.00 | 105% 0.95K to 1.95K | |
| 30-Dec-03 10:00 PM View: | Olukotun Adeoye Y Sr VP Clin & Reg Affairs, CMO | Esperion Therapeutics Inc/mi (ESPR) | 18-Nov-03 | Option Exercise | 3,200 | $5.52 | $17,664.00 | 100% 0 to 3.2K | |
| 01-Oct-03 10:00 PM View: | Krause Brian R VP Preclinical Res.& Discovery | Esperion Therapeutics Inc/mi (ESPR) | 30-Sep-03 | Acquisition (other) | 53 | $16.33 | $865.49 | 18% 0.3K to 0.35K | |
| 01-Oct-03 10:00 PM View: | Brinkerhoff William F VP Business Development | Esperion Therapeutics Inc/mi (ESPR) | 30-Sep-03 | Acquisition (other) | 22 | $16.33 | $359.26 | 2% 1.37K to 1.39K | |
| 12-Sep-03 10:00 PM View: | Brinkerhoff William F VP Business Development | Esperion Therapeutics Inc/mi (ESPR) | 11-Sep-03 | Option Exercise | 10,000 | $4.80 | $48,000.00 | 732% 1.37K to 11.37K | |
| 12-Sep-03 10:00 PM View: | Brinkerhoff William F VP Business Development | Esperion Therapeutics Inc/mi (ESPR) | 11-Sep-03 | Option Sale | 10,000 | $18.37 | $183,730.00 | (88%) 11.37K to 1.37K | |
| 15-Sep-03 10:00 PM View: | Thomas Frank E VP, Finance & Inves. Relations | Esperion Therapeutics Inc/mi (ESPR) | 11-Sep-03 | Option Exercise | 10,000 | $5.00 | $50,000.00 | 1311% 0.76K to 10.76K | |
| 15-Sep-03 10:00 PM View: | Thomas Frank E VP, Finance & Inves. Relations | Esperion Therapeutics Inc/mi (ESPR) | 11-Sep-03 | Option Sale | 10,000 | $18.40 | $184,020.00 | (93%) 10.76K to 0.76K | |
| 28-Aug-03 10:00 PM View: | Thomas Frank E VP, Finance & Inves. Relations | Esperion Therapeutics Inc/mi (ESPR) | 26-Aug-03 | Sale | 1,500 | $16.00 | $24,000.00 | (66%) 2.26K to 0.76K | |
| 28-Aug-03 10:00 PM View: | Dasseux Jean Louis H VP, Chemistry & Technologies | Esperion Therapeutics Inc/mi (ESPR) | 26-Aug-03 | Sale | 14,000 | $16.00 | $224,000.00 | (71%) 19.61K to 5.61K | |
| 28-Aug-03 10:00 PM View: | Newton Roger S President & CEO Director | Esperion Therapeutics Inc/mi (ESPR) | 26-Aug-03 | Sale | 95,000 | $16.00 | $1,520,000.00 | (14%) 667.29K to 572.29K | |
| 28-Aug-03 10:00 PM View: | Mayleben Timothy M Chief Operating Officer & CFO | Esperion Therapeutics Inc/mi (ESPR) | 26-Aug-03 | Sale | 26,500 | $16.00 | $424,000.00 | (35%) 76.22K to 49.72K | |
| 28-Aug-03 10:00 PM View: | Krause Brian R VP Preclinical Res.& Discovery | Esperion Therapeutics Inc/mi (ESPR) | 26-Aug-03 | Sale | 6,000 | $16.00 | $96,000.00 | (95%) 6.3K to 0.3K | |
| 28-Aug-03 10:00 PM View: | Brinkerhoff William F VP Business Development | Esperion Therapeutics Inc/mi (ESPR) | 26-Aug-03 | Sale | 3,000 | $16.00 | $48,000.00 | (69%) 4.37K to 1.37K | |
| 28-Aug-03 10:00 PM View: | More Eileen M Director | Esperion Therapeutics Inc/mi (ESPR) | 26-Aug-03 | Sale | 20,000 | $16.00 | $320,000.00 | (39%) 51.19K to 31.18K |
